Literature DB >> 15306750

The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

A Girolami1, M L Randi, S Gavasso, A M Lombardi, F Spiezia.   

Abstract

According to our personal experience and to the study of the literature, 11 cases of venous thrombosis have been described as sporadic reports in patients with severe (homozygous) factor XII (FXII) deficiencies. In every cases but 4, associated risk factors were found to be present (pregnancy, post-partum period, surgery, trauma, in dwelling catheter, AT deficiency, heterozygous factor V Leiden, Burger's disease). In some instances more then one condition was present. The four patients for whom no information is supplied, were cases gathered from old and logically incomplete files and therefore the existence of associated risk factors cannot be excluded. The papers which investigated the presence of venous thrombosis in cohorts of patients with homoxygous FXII deficiency demonstrated the occurrence of venous thrombosis in 2 additional cases out of a total of 63 patients investigated. In these latter cases thrombosis occurred during pregnancy. This brings the total number of patients with FXII deficiency who showed a venous thrombosis to 13. Only a few of these patients were investigated for the presence of concomitant congenital prothrombotic conditions. The conclusion of the study seem to suggest that the role played by FXII deficiency in the pathogenesis of venous thrombosis is minor, if any.

Entities:  

Mesh:

Year:  2004        PMID: 15306750     DOI: 10.1023/B:THRO.0000037670.42776.cd

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  32 in total

1.  Geographic distribution of the 20210 G to A prothrombin variant.

Authors:  F R Rosendaal; C J Doggen; A Zivelin; V R Arruda; M Aiach; D S Siscovick; A Hillarp; H H Watzke; F Bernardi; A M Cumming; F E Preston; P H Reitsma
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

2.  Thrombophilia with a combination of antithrombin III and factor XII deficiency.

Authors:  N Maurin; H Schunkert; H G Sieberth
Journal:  Thromb Haemost       Date:  1988-08-30       Impact factor: 5.249

3.  Variations of factor XII level during pregnancy in a woman with Hageman factor deficiency.

Authors:  J F Schved; J C Gris; S Neveu; P Mares; C Sarlat
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

4.  Recurrent thrombosis in a young woman with a circulating anticoagulant directed against factors XI and XII.

Authors:  H Aberg; I M Nilsson
Journal:  Acta Med Scand       Date:  1972-11

5.  Cholecystectomy in a patient with Hageman trait.

Authors:  A Girolami; A Maffei; A Brunetti; M Lazzarin
Journal:  Thromb Diath Haemorrh       Date:  1970-06-30

6.  Should factor XII assays be included in thrombophilia screening?

Authors:  M Winter; M Gallimore; D W Jones
Journal:  Lancet       Date:  1995-07-01       Impact factor: 79.321

7.  Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

Authors:  A Girolami; P Simioni; L Scarano; B Girolami; P Zerbinati
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

8.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

Authors:  R W Colman; A Bagdasarian; R C Talamo; C F Scott; M Seavey; J A Guimaraes; J V Pierce; A P Kaplan
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

9.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

10.  Factor XII clotting activity and antigen levels in patients with thromboembolic disease.

Authors:  R von Känel; W A Wuillemin; M Furlan; B Lämmle
Journal:  Blood Coagul Fibrinolysis       Date:  1992-10       Impact factor: 1.276

View more
  25 in total

Review 1.  Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Relationship between factor XII deficiency and thrombosis: the debate is still open?

Authors:  Gianfranco Lessiani; Angela Falco; Elvira Nicolucci; Giancarlo Rolandi; Giovanni Davì
Journal:  J Thromb Thrombolysis       Date:  2009-04-08       Impact factor: 2.300

3.  The association of a mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified.

Authors:  Antonio Girolami; Pamela Scarparo; Silvia Vettore
Journal:  J Thromb Thrombolysis       Date:  2009-03-13       Impact factor: 2.300

Review 4.  Pregnancies and oral contraceptive therapy in severe (homozygons) FXII deficiency: a study in 12 patients and review of the literature.

Authors:  A Girolami; N Zocca; B Girolami; A M Lombardi; F Fabris
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

5.  Sequence variation and genetic evolution at the human F12 locus: mapping quantitative trait nucleotides that influence FXII plasma levels.

Authors:  Francesc Calafell; Laura Almasy; Maria Sabater-Lleal; Alfonso Buil; Carolina Mordillo; Anna Ramírez-Soriano; Martin Sikora; Juan Carlos Souto; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Mol Genet       Date:  2009-11-23       Impact factor: 6.150

6.  Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Authors:  C Puy; E I Tucker; Z C Wong; D Gailani; S A Smith; S H Choi; J H Morrissey; A Gruber; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

7.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 8.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

9.  Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

Authors:  A Girolami; N Candeo; G Berti De Marinis; E Bonamigo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

10.  Polymorphism FXII 46C>T and cardiovascular risk: additional data from Spanish and Tunisian patients.

Authors:  Georgios Athanasiadis; Esther Esteban; Magdanela Gayà Vidal; Robert Carreras Torres; Raoudha Bahri; Pedro Moral
Journal:  BMC Res Notes       Date:  2009-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.